We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody
News

Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody

Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody
News

Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cobra Biologics Ltd and Algeta ASA have announced a new contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate (TTC) program.

The program will focus on the development of an undisclosed monoclonal antibody, which is highly selective for a validated cell surface target on hematological cancer cells, linked to Algeta's alpha-particle emitter thorium-227 (Th-227).

Under the terms of the contract manufacturing agreement, Cobra will be providing cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP production, as well as stability studies.

Algeta will be benefiting from Cobra’s maxXpress service, which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team and the Cello™ robotic clone selection system, to enable rapid clone selection and production of the monoclonal antibody.

Peter Coleman, CEO of Cobra Biologics, said: “We are delighted that Algeta have chosen Cobra as the manufacturer of a monoclonal antibody. Algeta’s contract forms part of a very successful year where we are seeing significant expansion in our antibody contract manufacturing as customers see the advantages Cobra’s comprehensive services provide."

Advertisement